Early and Late CNS Inflammation in Alzheimer's Disease: Two Extremes of a Continuum?

Trends in Pharmacological Sciences

Volumn 38, Issue 11, 2017, Pages 956-966

  Cuello, A Claudio ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CELECOXIB; INTERLEUKIN 10; INTERLEUKIN 1BETA; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CELL ACTIVATION; COGNITION; DISEASE ASSOCIATION; DISEASE COURSE; DOWN SYNDROME; HIPPOCAMPUS; MACROGLIA; NERVOUS SYSTEM INFLAMMATION; PHAGOCYTOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREM2 GENE; ANIMAL; DISEASE MODEL; ENCEPHALITIS; HUMAN; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALITIS; HUMANS;

EID: 85028554880     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.07.005     Document Type: Review

References (67)

1. Eikelenboom, P., et al. Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease. Alzheimers Res. Ther., 4, 2012, 15.
2. Alzheimer, A., Uber eine eigenartige Erkrankung der Hirnrinde. Allg Zeitschrift Psych 64 (1907), 146–148.
3. Fischer, O., Miliare Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmässige Veränderung der Hirnrinde bei seniler Demenz. Monatsschr Psychiat Neurol. 22 (1907), 361–372.
4. Goedert, M., Oskar Fischer and the study of dementia. Brain 132 (2009), 1102–1111.
5. Eikelenboom, P., Stam, F.C., Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 57 (1982), 239–242.
6. McGeer, P.L., et al. Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol. 76 (1988), 550–557.
7. McGeer, P.L., et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett. 79 (1987), 195–200.
8. Giometto, B., et al. Acute-phase proteins in Alzheimer's disease. Eur. Neurol. 28 (1988), 30–33.
9. McGeer, P.L., et al. Anti-inflammatory drugs and Alzheimer disease. Lancet, 335, 1990, 1037.
10. Tohoku, H.A., Inflammatory response in Alzheimer's disease. J. Exp. Med. 174 (1994), 295–303.
11. Metchnikoff, A., Lectures on the Comparative Pathology of Inflammation Delivered at The Pasteur Institute in 1891. 1893, Kegan Paul, Trench, Trubner & Co. (Starling F.A. and Starling, E.H., trans.).
12. Medawar, P.B., Immunity to homologous grafted skin. III. The fate of skin homographs transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br. J. Exp. Pathol. 29 (1948), 58–69.
13. Neuwelt, E.A., Clark, W.K., Unique aspects of central nervous system immunology. Neurosurgery 3 (1978), 419–430.
14. Wilcock, D.M., Neuroinflammatory phenotypes and their roles in Alzheimenr's disease. Neurodegener. Dis. 13 (2014), 183–185.
15. Kohli, P., Levy, B.D., Resolvins and protectins: mediating solutions to inflammation. Br. J. Pharmacol. 158 (2009), 960–971.
16. Wang, X., et al. Resolution of inflammation is altered in Alzheimer's disease. Alzheimers Dement. 11 (2015), 40–50.
17. Keren-Shaul, H., et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell 169 (2017), 1276–1290.
18. Hoozemans, J.J.M., et al. Neuroinflammation in Alzheimer's disease wanes with age. J. Neuroinflammation, 8, 2011, 171.
19. Heneka, M.T., et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 14 (2015), 388–405.
20. Latta, C.H., et al. Neuroinflammation in Alzheimer's disease; a source of heterogeneity and target for personalized therapy. Neuroscience 302 (2015), 103–111.
21. Wilcock, D.M., Griffin, W.S., Down's syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J. Neuroinflammation, 10, 2013, 84.
22. Wyss-Coray, T., Rogers, J., Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med., 2, 2012, a006346.
23. Birch, A.M., et al. Modulation of inflammation in transgenic models of Alzheimer's disease. J. Neuroinflammation, 11, 2014, 25.
24. Sastre, M., et al. Inflammatory risk factors and pathologies associated with Alzheimer's disease. J. Curr. Alzheimer Res. 8 (2011), 132–141.
25. Malm, T.M., et al. The evolving biology of microglia in Alzheimer's disease. Neurotherapeutics 12 (2015), 81–93.
26. Wiss-Coray, T., Mucke, L., Inflammation in neurodegenerative disease – a double-edged sword. Neuron 35 (2002), 419–432.
27. Weninger, S.C., Yankner, B., Inflammation and Alzheimer disease: the good, the bad, and the ugly. Nat. Med. 7 (2001), 527–528.
28. Naj, A.C., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 43 (2011), 436–441.
29. Griciuc, A., et al. Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron 78 (2013), 631–643.
30. Bradshaw, E.M., et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat. Neurosci. 16 (2013), 848–850.
31. Lampron, A., et al. Migration of bone marrow-derived cells into the central nervous system in models of neurodegeneration. J. Comp. Neurol. 521 (2013), 3863–3876.
32. Michaud, J.P., et al. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 1941–1946.
33. Chakrabarty, P., et al. IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron 85 (2015), 519–533.
34. Guillot-Sestier, M.V., et al. Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 85 (2015), 534–548.
35. Roussos, P., et al. The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's Dementia. Alzheimers Dement. 11 (2015), 1163–1170.
36. Tanzi, R.E., TREM 2 and risk of Alzheimer's disease: friend or foe?. N. Engl. J. Med. 372 (2015), 2564–2565.
37. Jay, T.R., et al. Disease progression-dependent effects of TREM2 deficiency in a mouse model of Alzheimer's disease. J. Neurosci. 37 (2017), 637–647.
38. Vlad, S.C., et al. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70 (2008), 1672–1677.
39. Szekely, C.A., et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. BMJ, 327, 2003, 128.
40. Etminan, M., et al. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Epidemiol. Rev. 24 (2002), 248–268.
41. Veld, B.A., et al. Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. Epidemiol. Rev. 24 (2002), 248–268.
42. McGeer, P.L., McGeer, E.G., The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 126 (2013), 479–497.
43. Miguel-Álvarez, M., et al. Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: a systematic review and meta-analysis of treatment effect. Drugs Aging 32 (2015), 139–147.
44. Gupta, P.P., et al. Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: a meta-analysis of randomized clinical trials. Alzheimers Dis. Other Demen. 30 (2015), 178–182.
45. Jaturapatporn, D., et al. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Cochrane Database Syst. Rev., 2012, CD006378.
46. ADAPT-FS Research Group, Follow-up evaluation of cognitive function in the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial and its Follow-up Study. Alzheimers Dement. 11 (2015), 216–225.
47. Breitner, J.C., et al. ADAPT: extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 7 (2011), 402–411.
48. Jack, C.R. Jr, et al. Update on hypothetical model of Alzheimer's disease biomarkers. Lancet Neurol. 12 (2013), 207–216.
49. Eikelenboom, P., et al. Neuroinflammation – an early event in both the history and pathogenesis of Alzheimer's disease. Neurodegener. Dis. 7 (2010), 38–41.
50. Parachikova, A., et al. Inflammatory changes parallel the early stages of Alzheimer disease. Neurobiol. Aging 28 (2007), 1821–18233.
51. Stefaniak, J., O'Brien, J., Imaging of neuroinflammation in dementia: a review. J. Neurol. Neurosurg. Psychiatry 87 (2016), 21–28.
52. Rodriguez-Vieitez, E., et al. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease. Brain 139 (2016), 922–936.
53. Head, E., et al. Aging in Down syndrome and the development of Alzheimer's disease neuropathology. Curr. Alzheimer Res. 13 (2016), 18–29.
54. Hartley, D., et al. Down syndrome and Alzheimer's disease: common pathways, common goals. Alzheimers Dement. 11 (2015), 700–709.
55. Carta, M.G., et al. Chemokines and pro-inflammatory cytokines in Down's syndrome: an early marker for Alzheimer-type dementia?. Psychother. Psychosom. 71 (2002), 233–236.
56. Licastro, F., et al. Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: relationship with dementia of Alzheimer's type. Int. J. Immunopathol. Pharmacol. 18 (2005), 165–172.
57. Iulita, M.F., et al. An inflammatory and trophic disconnect biomarker profile revealed in Down syndrome plasma: relation to cognitive decline and longitudinal evaluation. Alzheimers Dement. 12 (2016), 1132–1148.
58. Janelsins, M.C., et al. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J. Neuroinflammation, 2, 2005, 23.
59. Heneka, M.T., et al. Focal glial activation coincides with increased BACE1 activation and precedes amyloid plaque deposition in APP [V717I] transgenic mice. J. Neuroinflammation, 2, 2005, 22.
60. Bruno, M.A., et al. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J. Neuropathol. Exp. Neurol. 68 (2009), 1309–1318.
61. Ferretti, M.T., et al. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol. Aging 33 (2012), 1329–1342.
62. Cuello, A.C., et al. Preplaque (‘preclinical’) Aβ-induced inflammation and nerve growth factor deregulation in transgenic models of Alzheimer's disease-like amyloid pathology. Neurodegener. Dis. 10 (2012), 104–107.
63. Hanzel, C.E., et al. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol. Aging 35 (2014), 2249–2262.
64. Lim, G.P., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20 (2000), 5709–5714.
65. McAlpine, F.E., et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 34 (2009), 163–177.
66. Seabrook, T.J., et al. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. Glia 53 (2006), 776–782.
67. Ferretti, M.T., et al. Minocycline corrects early, pre-plaque neuroinflammation and inhibits BACE-1 in a transgenic model of Alzheimer's disease-like amyloid pathology. J. Neuroinflammation, 9, 2012, 62.